The estimated Net Worth of Peter Kissinger is at least 14.5 千$ dollars as of 20 September 2016. Peter Kissinger owns over 28,605 units of Chembio Diagnostics stock worth over 14,504$ and over the last 13 years Peter sold CEMI stock worth over 0$.
Peter has made over 3 trades of the Chembio Diagnostics stock since 2014, according to the Form 4 filled with the SEC. Most recently Peter exercised 28,605 units of CEMI stock worth 80,094$ on 20 September 2016.
The largest trade Peter's ever made was exercising 28,605 units of Chembio Diagnostics stock on 20 September 2016 worth over 80,094$. On average, Peter trades about 5,255 units every 112 days since 2011. As of 20 September 2016 Peter still owns at least 31,531 units of Chembio Diagnostics stock.
You can see the complete history of Peter Kissinger stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is 3661 HORSEBLOCK ROAD, , MEDFORD, NY, 11763.
Over the last 20 years, insiders at Chembio Diagnostics have traded over 909,824$ worth of Chembio Diagnostics stock and bought 3,754,893 units worth 1,696,058$ . The most active insiders traders include Credit Advisors, Llcpercept...、Lawrence A. Siebert、Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of 36,203$. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth 109,552$.
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
Chembio Diagnostics executives and other stock owners filed with the SEC include: